Loading...
•
Mar 31
Celsion Q1 2025 Earnings Report
Celsion reported reduced net loss and operating expenses in Q1 2025 while advancing clinical trials in ovarian cancer treatment.
Key Takeaways
IMUNON delivered a smaller net loss of $4.1 million in Q1 2025, supported by reduced R&D expenses and progress in its IMNN-001 Phase 3 trial. The company closed the quarter with $2.9 million in cash and expects to fund operations through late Q2 2025.
Net loss narrowed to $4.1 million from $4.9 million in Q1 2024.
Operating expenses dropped to $4.1 million, reflecting lower R&D costs.
Cash used in operations was $2.8 million, down from $5.9 million last year.
Company began first site enrollment for the Phase 3 OVATION 3 trial.
Celsion
Celsion
Forward Guidance
IMUNON plans to continue advancing its IMNN-001 program with the Phase 3 OVATION 3 trial and expects to maintain operations through late Q2 2025 with current capital resources.
Positive Outlook
- Initiation of Phase 3 OVATION 3 trial for IMNN-001.
- New data from OVATION 2 accepted for oral presentation at ASCO.
- Strong reduction in R&D expenses, improving financial efficiency.
- Sustained focus on advanced ovarian cancer treatment innovation.
- Demonstrated immunogenicity from PlaCCine DNA vaccine platform.
Challenges Ahead
- No revenue generated during the quarter.
- Cash and cash equivalents declined to $2.9 million.
- Operations only funded through late Q2 2025.
- Limited financial runway may require near-term capital raise.
- Ongoing net losses despite cost reductions.